Asset Details
Do you wish to reserve the book?
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
Do you wish to request the book?
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
2007
Overview
In this large, randomized, placebo-controlled trial, a quadrivalent vaccine (including human papillomavirus types 6, 11, 16 and 18) given at day 1, month 2, and month 6 was associated with a significant reduction in the occurrence of cervical intraepithelial neoplasia. No beneficial effect was observed on prevalent lesions. The prevention benefit for incident lesions associated with HPV-16 and HPV-18 appears to increase with time.
A quadrivalent vaccine (including human papillomavirus types 6, 11, 16 and 18) was associated with a significant reduction in the occurrence of cervical intraepithelial neoplasia. The prevention benefit for incident lesions associated with HPV-16 and HPV-18 appears to increase with time.
Cervical cancer is the second most common cancer in women and the leading cause of cancer-related death in many developing countries.
1
Although well-organized programs for Papanicolaou screening have led to a significant decline in mortality from cervical cancer in developed countries,
1
such programs are costly
2
and have not been effectively implemented in most developing countries.
3
Human papillomaviruses (HPVs) cause virtually all cervical cancers, with HPV types 16 (HPV-16) and 18 (HPV-18) responsible for approximately 70%.
4
When phase 3 trials of prophylactic HPV vaccines were in the planning stages, the vaccine advisory committee of the Food and Drug Administration (FDA) recommended . . .
Publisher
Massachusetts Medical Society
Subject
/ Adenocarcinoma - prevention & control
/ Adult
/ Biological and medical sciences
/ Cervical Intraepithelial Neoplasia - epidemiology
/ Cervical Intraepithelial Neoplasia - prevention & control
/ Female
/ Human papillomavirus 16 - genetics
/ Human papillomavirus 16 - isolation & purification
/ Human papillomavirus 18 - genetics
/ Human papillomavirus 18 - isolation & purification
/ Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
/ Humans
/ Medicinska och farmaceutiska grundvetenskaper
/ Microbiology in the Medical Area
/ Mikrobiologi inom det medicinska området
/ Papillomavirus Infections - prevention & control
/ Papillomavirus Vaccines - adverse effects
/ Public health. Hygiene-occupational medicine
